Adamas Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
27.19 M |
Public Float |
21.59 M |
Adamas Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$4.61 |
Market Cap |
$165.2 M |
Shares Outstanding |
27.53 M |
Public Float |
21.89 M |
Address |
1900 Powell Street Emeryville California 94608 United States |
Employees | - |
Website | http://www.adamaspharma.com |
Updated | 07/08/2019 |
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. |